. 2021 Jun 22;90(3):477–489. doi: 10.1002/ana.26137

TABLE 2.

Multivariable Models for the Following Outcomes: (A) Time to First Relapse, (B) sNfL Z‐scores, (C) sNfL Z‐scores in Untreated Patients, (D) Total T2w Lesion Count, (E) New/Enlarging T2w Lesion Count, (F) Multiple Sclerosis Severity Score and (G) Time to First Initiation of a heDM

A. Time to First Relapse	n	HR	CI	p
Male versus female	498	0.93	0.74, 1.17	0.528
Age	498	0.99	0.98, 1.00	0.237
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	114	1.45	0.93, 2.27	0.102
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	228	1.40	0.92, 2.14	0.115
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	110	1.94	1.24, 3.05	<0.01

B. sNfL Z‐scores	n	Est.	CI	p
Male versus female	3045	0.03	−0.18, 0.23	0.782
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	667	0.10	−0.27, 0.47	0.594
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	1394	0.12	−0.22, 0.46	0.502
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	716	0.41	0.04, 0.78	0.032

C. sNfL Z‐scores in Untreated Patients	n	Est.	CI	p
Male versus female	456	0.51	0.10, 0.92	0.016
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	100	0.71	0.06, 1.36	0.033
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	181	0.79	0.21, 1.38	<0.01
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	88	1.18	0.53, 1.83	<0.01

D. T2w Lesion Count	n	IRR	CI	p
Male versus female	1795	1.16	0.91, 1.48	0.226
Age	1795	1.02	1.01, 1.03	<0.01
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	389	1.66	1.08, 2.57	0.021
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	809	1.59	1.06, 2.37	0.023
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	414	2.53	1.63, 3.93	<0.01

E. New/Enlarging T2w Lesion Count	n	IRR	CI	p
Male versus female	838	0.93	0.55, 1.58	0.789
Age	838	0.98	0.96, 1.00	0.072
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	164	1.84	0.73, 4.62	0.195
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	387	1.61	0.70, 3.69	0.258
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	195	3.13	1.29, 7.58	0.011

F. Multiple Sclerosis Severity Score	n	Est.	CI	p
Male versus female	499	0.70	0.30, 1.10	<0.01
Age	499	0.06	0.04, 0.08	<0.01
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	114	0.73	0.01, 1.45	0.047
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	228	0.86	0.19, 1.52	0.012
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	111	1.11	0.38, 1.84	<0.01

G. Time to First Initiation of an heDMT	n	HR	CI	p
Male versus female	500	1.06	0.79, 1.42	0.715
Age	500	0.99	0.97,1.00	0.037
OCGB⁺/IgG_IF ⁻/IgM_IF ⁻ ^a	114	2.02	0.99, 4.14	0.055
OCGB⁺/IgG_IF ⁺/IgM_IF ⁻ ^a	229	2.09	1.04, 4.16	0.037
OCGB⁺/IgG_IF ⁺/IgM_IF ⁺ ^a	111	2.95	1.44, 6.02	<0.01

^{^a}

Comparator group: OCGB⁻/IgG_IF ⁻/IgM_IF ⁻: n = 46 patients.

CI = 95% confidence interval; heDMT = high‐efficacy disease‐modifying treatment; HR = hazard ratio; IgG_IF/M_IF = immunoglobulin G/M intrathecal fraction; OCGB⁺ = presence of oligoclonal IgG bands.